Gramee Oral Drops contain Granisetron at a concentration of 1mg per 5ml and are indicated for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative conditions. Granisetron is a selective 5-HT3 receptor antagonist that works by blocking serotonin receptors located in the central nervous system and gastrointestinal tract, thereby inhibiting the emetic signals triggered by cytotoxic agents or surgical stimuli. The oral drop formulation allows for flexible dosing, making it suitable for patients who have difficulty swallowing tablets or require dose adjustments. Gramee Oral Drops should be administered as directed by a healthcare professional, typically prior to the initiation of emetogenic therapy and continued as necessary to control symptoms. Common adverse effects may include headache, constipation, and dizziness, though the medication is generally well tolerated. Caution is advised in patients with hepatic impairment, and dose adjustments may be necessary. Granisetron does not exhibit significant interactions with most other drugs but should be used under medical supervision to monitor for potential side effects and efficacy. This medication is contraindicated in patients with known hypersensitivity to Granisetron or any component of the formulation. Proper storage conditions should be maintained to preserve the drug’s stability and effectiveness.